tbuckley/cabot-search huggingface dataset:
Abstract 12101: Family History of Coronary Heart Disease and Coronary Artery Calcium in South Asians and 4 Other Racial/Ethnic Groups in the US: The Mediators of Atherosclerosis in South Asians Living in America study and the Multi-Ethnic Study of Atherosclerosis
Authors: Jaideep Patel, Miguel Cainzos-Achirica, Namratha Kandula, Alka Kanaya, Roger S Blumenthal, Khurram Nasir, Michael J Blaha, Parag H Joshi
Journal: Circulation (2015)

Introduction: High coronary heart disease (CHD) rates among South Asians (SAs) are not fully explained by traditional risk factors. The association of a family history of CHD (FH) with subclinical atherosclerosis as measured by coronary artery calcium (CAC) in SAs is unknown. Hypothesis: FH is significantly and independently associated with CAC presence and burden in SAs and other ethnicities. Methods: We included all participants aged 45-84 years from two community-based populations: the MASALA study of SAs and the MESA study of Non-Hispanic Whites (NHWs), African Americans (AAs), Chinese Americans (CAs), and Hispanics (HPs). All participants underwent baseline CAC scanning. FH was defined as a self-reported history of CHD in a first-degree relative. We used multivariable regression models to assess the association of FH with CAC (&gt;0 and &gt;100) and likelihood ratio tests to assess the incremental predictive ability of FH to identify CAC (&gt;0 and &gt;100) when added to the 2013 ACC/AHA ASCVD risk estimate in each racial/ethnic group. Results: Baseline demographics are shown in the table. NHWs, AAs, and HPs with a FH had a significantly higher proportion of CAC&gt;0 and CAC&gt;100 than those without FH. In unadjusted and multivariable analyses, FH was significantly associated with CAC burden in NHWs, AAs, and HPs, but not in CAs or SAs (Table). Similarly, FH significantly added to the ASCVD risk estimate in predicting prevalent CAC&gt;0 and CAC&gt;100 in NHWs, AAs, and HPs (p-values &lt;0.01 for all), but not in CAs (p-value 0.151 and 0.362) or in SAs (p-value 0.778 and 0.216, respectively). In a sensitivity analysis, FH was significantly associated with very high CAC&gt;400 in SAs, but not in CAs. Conclusion: FH was strongly and independently associated with CAC burden in NHWs, AAs, and HPs; this association was weaker and non-significant in CAs and SA in the US. Understanding the reasons behind these findings will require evaluation in larger populations of CAs and SAs with detailed ascertainment of FH.
A typical sign on a plain knee radiograph
Authors: Paul T P W Burgers, Peter H C Den Hollander
Journal: BMJ (2016)

A healthy 23 year old football player presented a couple of hours after an episode of trauma to his left knee. When running, he had turned to the right while keeping the left foot fixed to the ground (external rotation-valgus stress). He had not heard or felt a pop or a click, but afterwards he was not able to bear weight. Immediate swelling occurred and the pain was localised medially. A radiograph was obtained (fig 1⇓).



Fig 1 

What abnormality is shown on the radiograph and what condition is it associated with?

### Answer

A lateral femoral notch sign or sulcus sign (red line) …
Recombinant Human Erythropoietin Administration Decreases the Frequency of Excessive Apoptosis in Erythroid Progenitors in the Model Mouse of Anemia Due to Chronic Renal Failure.
Authors: Tatsuo Oyake, Shigeki Ito, Shugo Kowata, Kazunori Murai, Yoji Ishida
Journal: Blood (2007)
Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer
Authors: Farzin Khosrow-Khavar, Soham Rej, Hui Yin, Armen Aprikian, Laurent Azoulay
Journal: Journal of Clinical Oncology (2017)

Purpose Recent observational studies have associated the use of androgen deprivation therapy (ADT) with an increased risk of dementia and Alzheimer’s disease, but these studies had limitations. The objective of this study was to determine whether the use of ADT is associated with an increased risk of dementia, including Alzheimer’s disease, in patients with prostate cancer. Patients and Methods Using the United Kingdom’s Clinical Practice Research Datalink, we assembled a cohort of 30,903 men newly diagnosed with nonmetastatic prostate cancer between April 1, 1988 and April 30, 2015, and observed them until April 30, 2016. Time-dependent Cox proportional hazards models were used to estimate adjusted hazard ratios with 95% CIs of dementia associated with the use of ADT compared with nonuse. ADT exposure was lagged by 1 year to account for delays associated with the diagnosis of dementia and to minimize reverse causality. Secondary analyses assessed whether the risk varied with cumulative duration of use and by ADT type. Results During a mean (standard deviation) follow-up of 4.3 (3.6) years, 799 patients were newly diagnosed with dementia (incidence, 6.0; 95% CI, 5.6 to 6.4) per 1,000 person-years. Compared with nonuse, ADT use was not associated with an increased risk of dementia (incidence, 7.4 v 4.4 per 1,000 person-years, respectively; adjusted hazard ratio, 1.02; 95% CI, 0.87 to 1.19). In secondary analyses, cumulative duration of use ( P for heterogeneity = .78) and no single type of ADT were associated with an increased risk of dementia. Conclusion In this population-based study, the use of ADT was not associated with an increased risk of dementia. Additional studies in different settings are needed to confirm these findings.
Phase I/II Study of Concurrent Chemoradiotherapy for Newly-Diagnosed, Localized Nasal NK/T-Cell Lymphoma: Results of a Phase I Portion of JCOG0211-DI.
Authors: Motoko Yamaguchi, Masahiko Oguchi, Kensei Tobinai, Nobuo Maseki, Takayo Suzuki, Yasufumi Masaki, Masanobu Nakata, Hiroyuki Hata, Noriko Usui, Izumi Wasada, Yoshikazu Kagami, Shigeo Nakamura, Tomomitsu Hotta, Kazuo Oshimi
Journal: Blood (2005)
Antiphospholipid Antibodies Promote Leukocyte-Endothelial Cell Adhesion by Antagonizing Endothelial NO Synthase Via b2GPI and ApoER2.
Authors: Cristina Tarango, Sangeetha Ramesh, Craig N. Morrell, Gail D. Thomas, Guillermina Girardi, Jane Salmon, Ivan S. Yuhanna, Joachim Herz, Philip Thorpe, Philip Shaul, Chieko Mineo
Journal: Blood (2009)
AB0143 Umbilical Cord Mesenchymal Stem Cells Increase Treg Cells via SHLA-G in Sle Patients
Authors: C. Chen, J. Liang, W. Chen, L. Sun
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Human leukocyte antigen-G (HLA-G) is a non-classical HLA class I molecule, exhibiting strong immunosuppressive properties by inducing the differentiation of regulatory T cells (Treg). Previous studies showed that umbilical cord mesenchymal stem cells (UCMSCs) transplantation could alleviate disease progression in SLE patients. However, the underlying mechanisms are largely unknown. <h3>Objectives</h3> To explore whether sHLA-G was involved in upregulation effects of MSCs on Treg, which contribute to the immune torlerance during SLE. <h3>Methods</h3> The level of sHLA-G was detected by ELISA in SLE patients and healthy controls. The correlations between the levels of sHLA-G and clinical features, percentages of HLA-G receptor ILT2 and Treg cells were analyzed by Sparman9s correlation test respectively. The percentage of ILT2 on T and B lymphocytes was examined by flow cytometry. PBMC were isolated from SLE patients and co-cultured with UC-MSCs for 3 days at different ratios (50:1, 10:1, 2:1) with or without HLA-G antibodies, and then the frequencies of CD4+CD25+Foxp3+T cells were determined by flow cytometry. <h3>Results</h3> The concentration of sHLA-G was increased in SLE patients compared with healthy control subjects (21.76 ng/mL ±1.206 VS 16.84 ng/mL ±1.656, <i>p</i> &lt;0.05). However, there was a negative correlation between sHLA-G levels and SLEDAI scores in active SLE patients (SLEDAI &gt;4). We found that sHLA-G levels were negative correlated with urea nitrogen, serum creatinine and 24-hour urine protein but positively correlated with platelet in SLE patients. What9s more, the sHLA-G levels were significantly lower in SLE patients with renal involvement compared with those without renal involvement. The expression of ILT2 in CD4+ T cells from SLE patients decreased significantly compared to controls. A positive relationship between the frequency of Treg cells and CD4<sup>+</sup>ILT2<sup>+</sup> T cells in SLE patients was found. The levels of sHLA-G increased 24 hours post MSCs transplantation. <i>In vitro</i> studies showed MSCs increased the frequency of Treg cells in SLE patients in a dose-dependent manner, which was partly abrogated by anti-HLA-G antibody. <h3>Conclusions</h3> Our results suggested that UCMSCs could alleviate SLE through upregulating Treg cells partly dependent on sHLA-G. <h3>Disclosure of Interest</h3> None declared
A Phase 2 Trial of Induction Chemotherapy with ABVD Followed By Brentuximab Vedotin Consolidation in Patients with Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma
Authors: Steven I. Park, Kristy L. Richards, Oludamilola Olajide, Nishitha M Reddy, Nilanjan Ghosh, Elizabeth E. Budde, Matthew C. Foster, Allison M. Deal, Jeanne F. Noe, Thomas C. Shea, Stephen M. Ansell
Journal: Blood (2014)
Comparable Outcomes with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients with or without Aplastic Anemia in a Prospective Korean PNH Registry
Authors: Jun Ho Jang, Jin Seok Kim, Deog-Yeon Jo, Je-Hwan Lee, Chul Won Choi, Hyeoung Joon Kim, Jong-Ho Won, Joo Seop Chung, Hawk Kim, Jae-Hoon Lee, Sang Kyun Sohn, Jeong A Kim, Jong Wook Lee
Journal: Blood (2015)
Multivariate and Subgroup Analyses of a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia
Authors: Jiri Mayer, Christopher Arthur, Jacques Delaunay, Grzegorz Mazur, Xavier Thomas, Agnieszka Wierzbowska, Mark M Jones, Erhan Berrak, Hagop M. Kantarjian
Journal: Blood (2012)
A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma.
Authors: Paul Richardson, R. Schlossman, N. Munshi, D. Avigan, S. Jagannath, M. Alsina, D. Doss, M. McKenney, K. Hande, M. Farrell, S. Gorelik, K. Colson, D. Warren, L. Lunde, R. Michelle, G. Cole, C. Mitsiades, T. Hideshima, T. Myers, R. Knight, K. Anderson
Journal: Blood (2005)
E3 Ligase c-CBL Mediates Ubiquitination-Proteasomal Degradation of BCR-ABL and Therapeutic Effects against BCR-ABL Leukemia.
Authors: Jianhua Mao, Xiaoyan Sun, Qun-Ye Zhang, Qiu-Hua Huang, Ping Liu, Yinyin Xie, Jing Lu, Saijuan Chen, Zhu Chen
Journal: Blood (2009)
PWE-088 UK Pilot Study of EUS Guided Fiducial Marker Placement for Image Guided Radiotherapy in Oesophageal Cancer: Initial Results of Feasibility and Radiotherapy Outcomes
Authors: V Mahesh, S Bangera, E Darling, K Dunn, L Telford, M Sivaramalingam
Journal: Gut (2016)

<h3>Introduction</h3> Fiducial markers (FM) help in radiotherapy planning (RT) by improving target delineation and optimise image guided radiotherapy (IGRT) during RT delivery. It helps in reducing interfraction RT setup uncertainty and improving the accuracy of treatment delivery. So far there are no studies in the UK that examined this technique with use of FM in Oesophageal cancers. We are hereby reporting the findings of our UK pilot study of FM guided 3 D Conformal RT and IGRT. <h3>Aim</h3> To evaluate the clinical outcomes of endoscopic ultrasound guided insertion of fiducial markers to demarcate oesophageal cancer for IGRT for Lancashire and South Cumbria cancer network (LSCCN) patients. <h3>Methods</h3> Institutional research and ethics committee approval was obtained. Our charity Rosemere Cancer Foundation funded this Prospective non-randomised cohort study. Cook EchoTip Ultra EUS Needles 22-F<sup>TM</sup> preloaded with 4 gold fiducial markers were used. Each marker measured 10 mm in length and 0.25μ in diameter. Olympus<sup>TM</sup> linear EUS was used to initially stage the tumour, followed by insertion of FM at the inferior and superior margins of the tumour. All patients with Oesophageal Squamous cancers at LSCCN from January 2015 to January 2016 considered for chemoradiotherapy were assessed for FM assisted IGRT. Contraindications include non-traversable tumours and patients with Oesophageal stent in situ. <h3>Results</h3> In total, 13 patients had 47 FM inserted under EUS guidance. Immediate CXR visualisation of FM was seen in 43/49 (88%). EUS guided FM insertion was feasible in all patients, no adverse events reported. Only 11 patients were eventually fit to undergo radiotherapy, of which data was available on 8 patients who received Radical 3 D conformal RT with 50 Gy. Markers were visualised in 21/27 (75%) on CT planning and during IGRT at treatment delivery using cone-beam CTs. Migration of the FM was seen with 2 markers, close to the actual lesion (in 2 patients). FM derived gross tumour length (GTV) on planning CT was similar to endoscopic tumour length (7.4 cm vs 8 cm). Mean GTV volume was 40.09 cubic cm (range: 18.57–80.1). Mean GTV length was 7.4 cm (range: 3.75–11.3). Mean PTV volume was 252.07 cubic cm (range: 135.4–357.2). Mean V20 for Lung was 19.16% (range: 13.1–28.37). FM assisted significantly in RT planning for tumour delineation. <h3>Conclusion</h3> FM for oesophageal cancer is technically feasible, safe, significantly improves target delineation for radiotherapy with excellent visibility for IGRT and acceptable stability (7.4% migration rate). Our completed data comparing FM based IGRT with conventional IGRT will help further clarifying its routine use in RT for patients with squamous cell oesophageal cancers. <h3>Disclosure of Interest</h3> None Declared
AB0907 Neck Pain Makes No Odds on Cervical Alignment in Patients with Temporomandibular Disorders
Authors: I. Coskun Benlidayi, R. Guzel, U. Tatli, F. Salimov, O. Keceli
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Despite the extensive research on the possible link between cervical posture and temporomandibular disorders (TMDs), it still remains as a highly controversial issue. The inconclusive results derived from the previous studies, might be in part due to the ignorance of neck pain, which usually accompanies TMDs. <h3>Objectives</h3> In the present study, we aimed to elucidate the impact of neck pain-if any-on cervical alignment in patients with TMDs. <h3>Methods</h3> °Patients diagnosed with TMDs according to the research diagnostic criteria for TMDs (RDC/TMD) between November 2013-November 2015 were included in the study. All subjects underwent lateral cervical x-ray evaluation and were asked to complete the RDC/TMD Axis II Biobehavioral Questionnaire for TMDs. Pain, disability and depression scores for TMD were calculated. Computerized measurement of the cervical lordosis angle was performed according to the C2-C7 cobb method. Additionally, disability score for neck pain was measured through Neck Disability Index (NDI) in patients with concomitant neck pain. The study sample was divided into two groups according to the presence of neck pain and a comparative analysis for cervical lordosis angle was carried out between groups. The relation of cervical malalignment with neck disability, TMD-associated pain, depression and disability was evaluated via Pearson9s correlation analysis. <h3>Results</h3> The study sample was consisted of 60 patients with a mean age of 31.2±10.8 years. The mean value for cervical lordosis angle in the whole group was 10.9±12.7°, which was consistent with hypolordosis. Cervical lordosis angle did not differ between patients with (n=28) and without (n=32) neck pain (12.2±12.8° versus 9.8±12.7°, respectively; p=0.46). Cervical alignment was correlated with neither neck disability nor TMD-related variables including pain intensity, depression and disability. <h3>Conclusions</h3> Patients with TMDs have hypolordotic cervical malalignment regardless of neck pain. The presence of neck pain makes no odds on patients9 cervical alignment. <h3>Disclosure of Interest</h3> None declared
OC-081 Nutritional Optimisation of Pre-Surgical Crohn’s Disease Patients with Enteral Nutrition Significantly Decreases Length of Stay and Need for a Stoma
Authors: KV Patel, AM Sandall, DV O’Hanlon, AA Darakhshan, AB Williams, E Westcott, PM Irving, MC Lomer, JD Sanderson
Journal: Gut (2016)

<h3>Introduction</h3> There is a lack of evidence for a clear nutritional optimisation strategy of pre-surgical Crohn’s disease (CD) patients. Limited data suggests that pre-surgical enteral nutrition (EN) increases albumin and decreases CRP as well as reducing anastomotic leakage, intra-abdominal abscess formation and wound infection. We aimed to assess the effect of nutritional optimisation of pre-surgical CD patients with EN on peri- and post-surgical outcomes and anthropometrics. <h3>Methods</h3> CD patients (n = 32) requiring ileal or ileocolonic resection were identified and nutritionally optimised pre-surgery using a minimum of 6 weeks EN (Modulen IBD, Nestle, Vevey, Switzerland) providing 75–100% nutritional requirements. Peri-surgical (albumin and CRP) and post-surgical (total length of stay, complication rate, readmission days and stoma formation) outcomes were compared with a retrospective sample of control patients (n = 35) who had not been nutritionally optimised. A subset of nutritionally optimised patients underwent anthropometric analysis pre and post EN. Continuous data are presented as mean ± sd and paired and independent t-tests were used for comparison where appropriate. Categorical data were compared using Chi squared tests. p &lt; 0.05 was considered significant. <h3>Results</h3> Nutritionally optimised patients had significantly shorter total length of stay compared with control patients (9.81 ± 9.97 d vs 16.34 ± 9.95 d, p = 0.009). Only 6 (19%) nutritionally optimised patients versus 19 (54%) control patients had stoma formation (p = 0.005). Nutritionally optimised patients had significantly fewer complication-related readmission days than control patients (0.69 ± 0.37 d vs 1.75 ± 3.64 d, p = 0.02). Twenty six (81%) nutritionally optimised patient had a normal albumin level pre-surgery versus 21 (60%) control patients (p = 0.002) and 20 (63%) nutritionally optimised patients had normal pre-surgery CRP versus 11 (31%) control patients (p = 0.001). Eleven patients (35.3 ± 13.3 years, 5 males) were included in the nutritionally optimised subset analysis. BMI did not change from pre to post EN (23.58 ± 5.04 kg/m2 to 23.03 ± 3.77 kg/m2; p = 0.336) nor did mid arm muscle circumference, waist circumference and handgrip strength. <h3>Conclusion</h3> Optimisation of nutrition pre-surgery in CD appears to reduce length of stay, stoma rate and additional hospital in-patient days for complications as well as improving albumin and CRP. However it is unclear what anthropometric measurements are useful to assess the effects of EN on nutritional status. <h3>Disclosure of Interest</h3> None Declared
OP0042 Humanised Anti-CD20 Antibodies Improve Depletion and Response in Sle Patients with Resistance To Rituximab: Results from The First 100 Patients at A Single Centre:
Authors: M.Y. Md Yusof, H. Cassamoali, T. Hawkins, A. Rawstron, E. Dunn, P. Emery, E.M. Vital
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rituximab (RTX) is effective for refractory SLE based on strong evidence for efficacy from open label evidence. We have observed cases of SLE patients who previously responded well to RTX developing anti-rituximab antibodies (HACA). We have therefore treated these patients with alternative, humanised anti-CD20 antibodies. <h3>Objectives</h3> To evaluate the incidence of secondary non-response to RTX and efficacy of switching to humanised anti-CD20 antibodies in SLE. <h3>Methods</h3> We conducted a retrospective observational study of the first 100 consecutive SLE patients treated with RTX at a single centre (total follow-up: 445 patient-years). Each cycle of RTX consisted of 2x1000mg infusions repeated on clinical relapse. Patients who demonstrated features of HACA, ie: infusion reaction &gt;24 hours after the second infusion with &lt;50% B cell depletion as analysed using HSFC were treated either with 2x1000mg ocrelizumab (OCR) or 2x700mg ofatumumab (OFT). Response was defined as improvement to ≤1 persistent BILAG B and no A/B flare. <h3>Results</h3> 94 patients with complete response data at 6 months were studied. In Cycle 1 (C1), 81/94 (86%) achieved a BILAG response. 1 patient with severe SLE whom B cell had not depleted and C1 non-responder was retreated with RTX but subsequently developed HACA. She was treated with OCR resulted in depletion and biological response ie: normalisation of anti-dsDNA but died 6 months later with multi-organ failure. Of the C1 responders, 63 patients received RTX on clinical relapse. Of this, 54/63 (86%) responded and 8/9 (13%) were non-responders due to HACA. Of the C2 non-responders, 3/9 patients were treated with OCR resulted in depletion in 2/3 and all responded. 1/9 was treated with OFT achieved depletion for the first time as well as stabilisation of renal function. In C3, 1 had HACA and was treated with OFT, resulted in depletion and response. <h3>Conclusions</h3> Following initial response to RTX, the incidence of secondary non-response was 15%, mostly due to HACA. Switching to alternative humanised anti-CD20 antibodies improves depletion and clinical response in rituximab-resistant patients in this largest case series to date. Humanised anti-CD20 may be more appropriate than RTX in SLE. <h3>Disclosure of Interest</h3> None declared
Genomic and Molecular Properties of Relapsed CNS Lymphoma Using Novel Primary Meningeal Lymphoma Cell Lines and Intracranial Xenografts,
Authors: Hua-Xin Gao, Shawn Anderson, Lingjing Chen, Cigall Kadoch, Byron C Hann, Clifford Lowell, Colin Collins, James L. Rubenstein
Journal: Blood (2011)